At the origin of Aβ with ADAM10

Abstract

Alzheimer's Disease Intracellular accumulation of insoluble amyloid β peptide (Aβ) oligomers is a major pathogenic event in Alzheimer's disease (AD). Cleavage of amyloid precursor protein (APP) by β- and γ-secretases generates insoluble Aβ peptides. On the contrary, α-secretase cleaves APP to form sAPPα, a soluble, neuroprotective fragment. ADAM10, a major α-secretase, is thought to play a role in AD; however, the mechanisms mediating ADAM10 modulation are unclear. Nakamura et al. now show that an ADAM10 inhibitor called RECK is increased in human AD brain samples. The authors found that RECK is controlled by glycerophosphodiester phosphodiesterase 2, and ablation of this enzyme or RECK elevation in mice promotes insoluble Aβ oligomer formation and accelerates AD pathology. Targeting this pathway might reduce Aβ pathology in AD. Sci. Transl. Med. 13 , eabe6178 (2021).